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Abstract—Adelivery system for vanadiumwas developedusing poly(¯-propiolactone)(P¯PL) lms.
The release kinetics of a complex of vanadium (IV) with aspirin (VOAspi) was evaluated with lms
prepared from polymers of differentmolecularweights, as well as with variabledrug load. A sustained
release of vanadium over 7 days was achieved. The drug release kinetics depends on contributions
from two factors: (a) diffusion of the drug; and (b) erosion of the P¯PL lm. The experimental
data at an early stage of release were tted with a diffusion model, which allowed determination of
the diffusion coefcient of the drug. VOAspi does not show strong interaction with the polymer, as
demonstrated by the low apparent partition coefcient (approximately10¡2). UMR106 osteosarcoma
cells were used as a model to evaluate the anticarcinogenic effects of the VOAspi released from the
P¯PL lm. VOAspi–P¯PL lm inhibited cell proliferation in a dose-response manner and induced
formation of approximately half of the thiobarbituric acid reactive substances (TBARS), an index
of lipid peroxidation, compared to that with free VOAspi in solution. The unloaded P¯PL lm did
not generate cytotoxicity, as evaluated by cell growth and TBARS. Thus, the polymer-embedded
VOAspi retained the antiproliferative effects showing lower cytotoxicity than the free drug. Results
with VOAspi–P¯PL lms suggest that this delivery system may have promising biomedical and
therapeutic applications.
Key words: Poly(¯-propiolactone);diffusionmodel; vanadium; osteosarcoma cells; cell proliferation;
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INTRODUCTION
During the past decade, various controlled release drug delivery systems based on
polymeric materials have been developed for biomedical use [1, 2]. Intravenous
or oral use of some of these delivery systems could lead to undesirable toxicity
or reduced bioavailability of the drug [3]. Implantable drug delivery systems,
on the other hand, could be an alternative to optimize the therapeutic prole of
specic drugs. However, these devices should fulll several criteria for biomedical
applications, such as biocompatibility, controlled biodegradation of the polymer,
lack of local and systemic toxicity, and a sustained delivery of the drugs.
Vanadium compounds have been investigated as alternative therapeutic agents for
use in diabetes. However, toxic effects of these agents after chronic use have been
reported [4–6]. For these reasons, there is great interest in the synthesis of new
vanadium derivatives with different ligands such as vanadium (IV) complexed either
with maltol [7] or with aspirin (VOAspi) [8]. In mammals, vanadium is mainly
stored in bones and kidney [9]. Using an in vitro model of osteoblast-like cells in
culture, we have previously shown that vanadium exerts a biphasic effect: while
low concentrations stimulate, high doses induce inhibition of osteoblast growth
and differentiation, as well as morphological transformations [5, 6, 10–13]. In
particular, VOAspi seems to be more potent than uncomplexed vanadyl salt in
inhibiting the growth of osteoblast-like cells [8].
In addition, the antineoplastic effects of vanadium have been demonstrated
for both in vitro, and in vivo models [14–16]. In order to avoid systemic
toxicity, Jackson et al. [14] developed a device for vanadium release from a
poly("-caprolactone) paste that was effective in the prevention of re-growth of
tumors in laboratory animal models. Using these types of devices for delivery,
organic–vanadium complex could be conveniently delivered in a controlled fashion,
thus resulting in reduced toxicity and better therapeutic effectiveness than a bolus
administration.
The poly(¯-propiolactone) (P¯PL) used in the present study has been synthesized
and previously physicochemically characterized in our laboratory [17, 18]. This
polymer is structurally similar to those widely used in controlled release systems,
such as the polyglycolic and polylactic copolymers that are biodegradable and
biocompatible polyesters [3]. However, no information on P¯PL is available on
its possible biomedical application.
In this study, we have developed a delivery system for VOAspi using P¯PL
polymeric lms. In a series of in vitro studies, we have evaluated the delivery
kinetics of VOAspi complex from P¯PL lms of different average molecular
weights, as well as the effect of the drug loading in the polymeric lms. In
addition, we have investigated the effects of controlled release of vanadium on
the proliferation, lipid peroxidation, and morphological alterations of UMR106
osteosarcoma cells in culture.
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MATERIALS AND METHODS
Materials
Chloroform, methanol, vanadium chloride, and vanadium (IV) oxide sulfate (vana-
dyl sulfate) were provided by Merck (Darmstadt, Germany), and used without
further purication. Tissue culture asks and multiwell plates were purchased from
Corning (Princeton, NJ, USA); Dulbecco’s Modied Eagles Medium (DMEM) and
trypsin-EDTA were purchased from Gibco (Gaithersburg, MD, USA). Fetal bovine
serum (FBS) was obtained from Gen (Buenos Aires, Argentina). A complex of
vanadyl with aspirin (VOAspi) was synthesized and characterized as previously
described [8]. Briey, aspirin and VOCl2 in a 2 : 1 ratio were mixed in 96% ethanol,
the green oil formed was successively washed with water, and the resulting solid
was ltered and dried until constant weight.
Synthesis and characterization of poly(¯-propiolactone)
The synthesis and characterization of P¯PL have been previously reported [17, 18].
Table 1 shows the relevant properties of the polymer samples used in this study. The
changes in the molecular weight and molecular weight distribution were followed
by size exclusion chromatography (SEC) in a LKB-2249 instrument at 25±C. A
series of ¹-Styragel columns, ranging in pore size 106, 105 , 104, 103 Å, were used
with chloroform as an eluent. The polymer concentration was 4–5 mgml¡1 and
the ow rate was 0.5 mlmin¡1 . The polymer was detected with a differential
refractometer detector (Waters R401) and calibration was done by the standard
procedure, as described previously [17, 18].
Preparation of the cast lms
Drug-containing P¯PL lms were prepared by solvent casting. A solution of
the P¯PL polymer in chloroform (5% w/w) was prepared and different amounts
(10–30% w/w) of the VOAspi were added to the polymer solution. Aliquots of the
clear solution of the drug-containing polymer were poured onto glass Petri dishes
(5 cm diameter), and the solvent was allowed to evaporate at room temperature for
several days. The resulting lms were dried under vacuum until constant weight,
and stored in a desiccator until use. The thickness of the lms (50–100 ¹m) was
measured using a micrometer.
Table 1.
Physicochemical properties of the P¯PL polymers
Sample Intrinsic viscosity, Viscosity average molecular Polydispersity index
[´] (ml g¡1) weight,M´ (g mol¡1) (M´=Mn)
P¯PL-43 55.9 42 700 1.4
P¯PL-51 63.1 51 300 2.0
P¯PL-112 112.0 112200 1.4
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Infrared spectra of the VOAspi–P¯PL lms and VOAspi in a KBr pellet were
recorded on a Perkin Elmer 580B spectrophotometer. The characteristic in-
frared bands previously described for the drug [8] were also observed in the
VOAspi–P¯PL lms, indicating that no chemical structural changes in the VOAspi
had occurred after its incorporation into the polymeric lm.
Vanadium release kinetic studies
Drug release experiments with lm samples (5 cm diameter) were carried out in
tubes containing 5 ml of 0.1 M phosphate buffer (PBS) (pH 7.4) and 100 ¹gml¡1
bovine serum albumin, at 37±C. At appropriate times (every 15 min during the initial
2 h, then every hour until 5 h, and nally every day for 7 days), the supernatants were
removed and replaced by 5 ml of fresh buffer. The time-dependent release of the
drug was followed by monitoring the amount of VOAspi present in the supernatant
medium, using a CECIL 2000 UV-visible spectrophotometer (¸max D 295 nm).
A linear calibration curve of VOAspi concentration vs absorbance at 295 nm was
obtained using VOAspi standards in the range 0–50 ¹gml¡1. At the end of the
drug-release experiments, samples of the lms were recovered to evaluate possible
changes in the molecular weight distribution of the P¯PL polymer.
Water content of P¯PL lms
The maximum swelling and water absorption capacity of the polymeric lms were
determined as follows. The P¯PL lms were weighed (w0 ) and then immersed in
the PBS buffer at 37±C for predetermined times. After wiping the surface with
paper, the lms were weighed in the wet state .w/. Then the lms were dried
in vacuum overnight at room temperature and weighed in the dried state. The
weight of the nal dry lm was wd. The water content of the lm was obtained
as the difference between w, the weight of the water saturated lm and w0, the
weight of the initial dried lm. The percentage of swelling of the lm is dened as:
%Sw D 100.w ¡ w0/=w0.
VOAspi–P¯PL interaction
The interaction between VOAspi and the P¯PL polymer was estimated through
the apparent partition coefcient of the drug (Kapp ), according to the procedure
of Miyajima [19]. Kapp was determined from the initial and equilibrium drug
concentration in the medium (C0 and Ce, respectively) after incubation of the drug
loaded lms in the PBS buffer for 24, 48, or 72 h using Eq. (1):
Kapp D 10.C0 ¡ Ce/=wCe; (1)
where w is the weight of the lm after immersion in the buffer.
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Drug release kinetic analysis
The temporal dependence of the VOAspi released at time t , from the lm of
thickness 2L was described by two different unidimensional diffusion models [20].
At the initial time, t D 0, the drug concentration was assumed to be constant
throughout the lm.
Model 1. At t > 0, it was assumed that the drug concentration in the liquid near
the surface of the lm, Csup, was higher than the concentration in the surrounding
environment, C1 (Csup > C1). This condition allowed us to take into account an
additional mass transfer resistance from the aqueous layer near the surface of the
lm.
Model 2. At t > 0, it was assumed that Csup D C1. This condition represents
an ideal situation indicating an instantaneous uniform distribution of the drug
throughout the aqueous media.
The cumulative amount of drug released at time t ,Mt, in the above two models is
mathematically expressed by:
Mt=M1 D 1¡
1X
nD1
2G2
¯2n .¯
2
n C G2 C G/
exp
³
¡¯
2
nD
L2
t
´
; (2)
where ¯n values are the positive roots of:
¯n tg¯n D G D L=.D=h/; (3)
and M1 represents the cumulative amount of drug released at innite time, which
is considered as constant. D is the diffusion coefcient of the drug, h is the mass
transfer coefcient in the boundary layer, and the ratio D=h is the thickness of the
boundary layer. This parameter vanishes in the Model 2 but was a nite value in the
Model 1.
Cell culture and incubations
UMR106 rat osteosarcoma-derived cells were grown in 75-cm2 asks at 37±C
in a humidied 5% CO2 atmosphere in DMEM supplemented with 100 Uml¡1
penicillin, 100 ¹gml¡1 streptomycin, and 10% (v/v) fetal bovine serum. When
70–80% conuence was reached, cells were sub-cultured using 0.1% trypsin–1 mM
EDTA in CaC2 –MgC2-free PBS [10, 11]. For experiments presented in this study,
cells were seeded in six-well plates at a density of 2:5 £ 104 cells per well, the
medium was replaced by serum-free DMEM and cells were incubated for 24 h
with different concentrations of VOAspi, vanadium–P¯PL lms, or medium alone
(basal control), under the conditions described in the legends of gures. Under these
conditions, FBS does not interfere with the measurement of VOAspi in the medium.
However, the growth factors present in the serum could alter the effect of vanadium
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on cell proliferation. Control cells did not show any apparent alterations after being
serum starved for 24 h.
Studies of cell growth
In order to determine cell growth, the monolayers were washed twice with PBS,
xed with methanol for 5 min at room temperature, and stained with a solution
of Giemsa for 10 min [13]. The plates were then washed with water and the cell
number evaluated by counting the stained nuclei in ten elds per well. The mitotic
index was dened as the number of mitotic gures per eld over the total number
of cells per eld.
Lipid peroxidation
To measure the extent of lipid peroxidation, the production of thiobarbituric acid
reactive substances (TBARS) was evaluated as previously reported [5] by using
the method described by Ohkawa et al. [21]. Protein content in the cell extract
was assessed by the method of Bradford [22]. The lipid peroxide levels were
expressed in terms of nmol of malondialdehyde per mg protein, using 1,1,3,3-
tetramethoxypropane as the standard.
Statistical analysis
For each experimental condition, at least three separate experiments were performed
in triplicate. Data were expressed as the mean § SEM. Statistical differences were
analyzed using a Student’s t-test.
RESULTS AND DISCUSSION
VOAspi release kinetics
Figure 1 shows the time course of the percent release of vanadium compound
from the P¯PL lm containing various concentrations of the drug. The time was
normalized by dividing the square of the sample half-thickness, L2, to account
for differences in sample thickness when comparing data from multiple samples.
The drug release prole of the lms containing 10–23% w/w of VOAspi was
comparable. However, the lm containing 30% w/w drug showed relatively faster
initial release of VOAspi. The kinetic analysis shows initially a fast release rate,
followed by a constant rate of release over 7 days.
The experimental data were tted with the diffusion models with three and two
parameters (models 1 and 2, respectively). All the data showed the same trend.
Within experimental error, both models conrm the results for a diffusion time
period of time zero up to 2 h. Figure 2 shows the results obtained with a P¯PL-51
lm with a half thickness of 50 ¹m. Model 1 predicts a diffusion coefcient
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Figure 1. Effect of drug content on VOAspi release from P¯PL-51 lm at 37±C.
Figure 2. Fractional drug release up to 2 h. Sample: P¯PL-51, 30%VOAspi,L D 50¹m. Parameters
are: D D 0:48£ 10¡10 cm2 s¡1, D=h D 4:8 ¹m (model 1); D D 0:58 £ 10¡10 cm2 s¡1 (model 2).
D D 0:48 £ 10¡10 cm2 s¡1 and a thickness of the boundary layer D=h D 4:8 ¹m,
i.e. one tenth of the lm thickness. A zero value of this layer (Model 2) predicts a
higher diffusion coefcient D D 0:58 £ 10¡10 cm2 s¡1, as expected from physical
considerations.
For longer release times, up to 5 h, Model 1 provides a better t of the
experimental data than Model 2 and the corresponding t parameters are D D
0:30 £ 10¡10 cm2 s¡1, D=h D 5:8 ¹m (Fig. 3). Nevertheless, at these longer time
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Figure 3. Fractional drug release up to 5 h. Sample: P¯PL-51, 30%VOAspi,L D 50¹m. Parameters
are: D D 0:30£ 10¡10 cm2 s¡1, D=h D 5:8 ¹m (Model 1).
Figure 4. Effect of the molecularweight of P¯PL on VOAspi release at 37±C. The drug concentration
was 30% (w/w) in all polymeric preparations.
periods, the one-dimensional model achieved a constant plateau while experimental
data showed a monotonic increase of the accumulative release mass, suggesting the
existence of complementary effects on the release.
The effect of the molecular weight of P¯PL on the drug release prole is shown
in Fig. 4. The concentration of drug in all polymer lm samples was kept constant
at 30% (w/w). No signicant effect on the molecular weight of the polymer in the
range of 4£ 104 to 1:2 £ 105 gmol¡1 was found on the release kinetics. A similar
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Table 2.
Effect of the time of degradation of P¯PL-51 on the molecular weight averages and polydispersity
index
P¯PL-51 0 day 2 days 7 days
Number average
molecular weight (Mn) 25 270 23 220 13 730
Viscosity average
molecular weightM´ 51 280 48 430 32 080
Polydispersity index
.M´=Mn/ 2.0 2.1 2.3
effect was observed by Wang [23] on aspirin release from poly(lactic-glycolic
acid) of low molecular weight (approximately 103 gmol¡1 ), although, signicant
dependence of the drug release on the molecular weight of this kind of polyesters
has been reported by other investigators [24].
In order to assess the physical and chemical erosion of the P¯PL lms, the
molecular weight distribution of the polymer was analyzed after incubation of
the drug loaded lms in PBS buffer. The chromatographic analysis (data not
shown) demonstrated that for up to the rst 2 days of incubation in PBS buffer,
no signicant changes in the molecular weight distribution of the polymer were
observed, suggesting that under these conditions, minimal degradation of the
polymer occurred. Table 2 shows the changes in different molecular weight
averages and the calculated polydispersity indexes. After the rst 2 days, the
molecular weights were decreased and the polydispersity index increased, due to
the random nature of the hydrolytic degradative mechanism.
Water content
Figure 5 shows the swelling behavior of the unloaded P¯PL lm at 37±C in PBS
buffer pH 7.4, which attained equilibrium after 1.5 h. Although, the water content
of P¯PL lms is lower than the water content of other similar polyesters [25], it is
in agreement with other unloaded systems, where there is no osmotic effect [26].
The early-time phase of water transport in the polymer lm is shown in the insert of
Fig. 5, and veries a power law behavior [27]:
%Sw D ktn; (4)
where Sw is the percentage of swelling of the lm, k is a constant, n is a diffusional
exponent that determines the transport mechanism, and t is the time of the swelling.
The n exponent was obtained as n D 0:49 § 0:03, which indicates a Fickian water
transport mechanism similar to other hydrophobic polymers [27].
No changes were observed in the dry weight of these lm samples (wd) during
the 8 h of the swelling experiment. This observation is in agreement with the size
exclusion chromatography analysis displayed in Table 2.
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Figure 5. Percentage of swelling of a P¯PL sample as a function of time at 37±C. Insert: Log– log
graph at initial stage.
VOAspi–P¯PL interaction
The possible VOAspi–P¯PL interaction was evaluated by measuring the apparent
partition coefcient at neutral pH. TheKapp, obtained after 1 to 3 days of incubation
at 37±C in a diluted VOAspi solution, was of the order of 10¡2 . This result was
anticipated from the neutral nature of the VOAspi compound and the fact that no
relevant P¯PL erosion was observed before 2 days, suggesting a lack of strong
drug–polymer interaction.
Effect of VOAspi-released from P¯PL lms on osteoblast growth
In this study UMR106 osteosarcoma cells were used as a model to evaluate
the anticarcinogenic effects of the VOAspi-released from the P¯PL lm. After
overnight incubation in a serum-free media with or without vanadium, cells were
xed, stained with Giemsa, and examined by light microscopy (Fig. 6). The
control cells (media alone) showed a polygonal morphology with well stained nuclei
and cytoplasms with processes connecting neighboring cells (Fig. 6A). Several
mitotic gures were also observed. A solution of free 0.1 mM VOAspi induced
a signicant decrease in the number of surviving cells, as well as morphological
alterations (Fig. 6B). The cytoplasm showed a strong condensation with loss of
processes. When the vanadium compound was released in a sustained manner from
the 10% w/w VOAspi–P¯PL lm, a decrease in the cell number was observed
with moderate changes in the cell morphology (Fig. 6C). As evaluated in parallel
experiments, under this condition, the concentration of VOAspi-released into the
culture medium over 24 h was 0.5 mM. However, incubation of the cells with a
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Figure 6. UMR106 cells cultured in: (A) DMEM alone (basal); (B) 0.1 mM free VOAspi; (C) 10%
(w/w) VOAspi–P¯PL lm; and (D) 30% (w/w) VOAspi–P¯PL lm, at 37±C after 24 h. At the end
of the incubation, cells were xed and stained with Giemsa (450£).
lm with a higher load of VOAspi (30% w/w) induced a strong cytotoxic effect
on the UMR106 cells (Fig. 6D). A few cells survived under these conditions and
showed a reduction of cytoplasm and a pronounced condensation of the nuclei.
A concentration of 2.5 mM VOAspi in the media was observed after overnight
incubations with 30% w/w drug-loaded lm.
In the control experiments, the effect of a solution of 0.1 mM aspirin or the un-
loaded P¯PL lm (without vanadium) was also evaluated for possible cytotoxicity.
In both cases, the cells grew well, with no morphological alterations in comparison
with control cell cultures without drug or polymer lm. These observations suggest
lack of toxicity either of aspirin that could have been released from the VOAspi
complex, or the monomer from the P¯PL lm.
UMR106 growth was also evaluated by adding different amounts of the 10% w/w
VOAspi–P¯PL lm in the culture media. As can be seen in Fig. 7, VOAspi
inhibited cell proliferation in a dose-dependent manner, with an ED50 D 0:45 mM
(50% surviving cells). In contrast, the ED50 value for free VOAspi (without
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Figure 7. Dose-response curve of VOAspi on cell proliferation. UMR106 osteoblastswere incubated
in DMEM alone (basal) or with the addition of various amounts of 10% w/w VOAspi–P¯PL lm or
free VOAspi, at 37±C for 24 h. At the end of this period, cells were xed, stained with Giemsa and
the nuclei counted in 10 elds per well. The results are presented as the mean §SEM.
polymer) was only 0.25 mM. Thus, VOAspi released from the P¯PL lm induced
an antiproliferative effect on UMR106 cells but with less cytotoxicity than the free
VOAspi. On the other hand, a 30% w/w VOAspi–P¯PL lm strongly inhibited cell
proliferation, with a 10% cell survival after overnight incubation (data not shown).
The mitotic index (MI) was assessed in the control as well as in the VOAspi-treated
cultures. Under basal conditions, a MI D 0:018 § 4 £ 10¡3 was found for the
UMR106 cells. TheMI was zero for the cells cultured either with a 0.1 mM solution
of VOAspi or with 0.3 mM VOAspi released from the P¯PL lms, indicating an
arrest of the proliferative process under these conditions.
These results suggest that VOAspi embedded in the polymer retained the antipro-
liferative effects previously reported [8] in osteosarcoma cells with lower cytotoxi-
city than the free drug.
Oxidative stress studies
We have previously shown that vanadium compounds generate reactive oxygen
species in osteoblast-like cells, and produce an oxidative stress [5]. Figure 8 shows
that vanadium-induced TBARS formation is increased in a concentration-dependent
manner. As can be seen, while 0.25 mM of free VOAspi was highly toxic (i.e. an
increase of 370% TBARS over basal value), an equivalent concentration of VOAspi
released from the controlled delivery system induced approximately half as much
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Figure 8. Effect of VOAspi on lipid peroxidation. UMR106 cells were incubated in DMEM alone
(basal) or with the addition of different concentrations of free VOAspi in solution or with various
amounts of 10% w/w VOAspi–P¯PL lm at 37±C for 4 h. The lipid peroxidation was evaluated by
assaying the TBARS production as described in Materials and Methods.
of TBARS formation. However, at concentrations of VOAspi greater than 0.45 mM,
the extent of lipoperoxidation was the same whether the drug was free released from
the P¯PL lms. In control experiments, 0.1 mM aspirin or the unloaded P¯PL lm
did not generate lipid peroxidation in the UMR106 osteosarcoma cells (data not
shown).
CONCLUSIONS
Based on the data presented in this communication, P¯PL lm appears to be
a promising polymer-based delivery approach for drugs requiring sustained and
controlled delivery. The release at the initial stage is dominated by a diffusion-based
mechanism. Swelling experiments demonstrated a rapid diffusion of water into the
lm; thus allowing for controlled diffusion of the drug out of the lm. The two
mathematical models used to analyze the data support the experimental results up
to 5 hours and their corresponding diffusion coefcient do not display signicative
differences from each other. Experimental results obtained over longer time periods
could be described by erosion effects due to degradation of the polymer, which
is more relevant after 2 days, as shown by our size exclusion chromatography
experiments.
The P¯PL lm does not cause toxic effects on cells in culture suggesting a good
biocompatibility.
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The results obtained with VOAspi–P¯PL lm and UMR106 cells point towards
a promising application of this system in antitumor chemotherapy. The morpho-
logical and biochemical experimental evidence presented in this study supports the
concept that sustained released VOAspi maintains its antiproliferative action on os-
teosarcoma cells, with substantially lower cytotoxicity than that previously reported
for this drug in solution.
The polymeric drug delivery system described in this communication provides
a sustained release of a vanadium–aspirin complex for up to 7 days. The
system is potentially useful for a topical application of selected drugs for cancer
chemotherapy. Further experiments in appropriated animal models are needed to
determine its full utility.
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